| Primary |
| Chronic Lymphocytic Leukaemia |
19.3% |
| Prophylaxis Against Graft Versus Host Disease |
16.5% |
| Stem Cell Transplant |
12.3% |
| Acute Myeloid Leukaemia |
9.2% |
| Bone Marrow Conditioning Regimen |
9.0% |
| Prophylaxis |
4.7% |
| Infection Prophylaxis |
4.4% |
| Antifungal Prophylaxis |
4.1% |
| Cord Blood Transplant Therapy |
2.6% |
| Immunosuppression |
2.6% |
| Non-hodgkin's Lymphoma |
2.1% |
| Antiviral Prophylaxis |
2.1% |
| Allogenic Bone Marrow Transplantation Therapy |
1.9% |
| B-cell Lymphoma |
1.6% |
| Haematological Malignancy |
1.5% |
| Drug Use For Unknown Indication |
1.5% |
| Chronic Lymphocytic Leukaemia Recurrent |
1.3% |
| Bone Marrow Transplant |
1.2% |
| Convulsion Prophylaxis |
1.1% |
| Graft Versus Host Disease |
1.1% |
|
| Pyrexia |
8.3% |
| Sepsis |
7.3% |
| Infection |
6.8% |
| Transplant Failure |
6.8% |
| Vomiting |
6.8% |
| Septic Shock |
5.9% |
| Thrombocytopenia |
5.9% |
| Graft Versus Host Disease |
5.4% |
| Venoocclusive Liver Disease |
5.4% |
| Multi-organ Failure |
4.9% |
| Respiratory Failure |
4.9% |
| Venoocclusive Disease |
4.9% |
| Myelodysplastic Syndrome |
3.9% |
| Stomatitis |
3.9% |
| Lung Neoplasm Malignant |
3.4% |
| Thrombotic Microangiopathy |
3.4% |
| Weight Decreased |
3.4% |
| Hepatitis B |
2.9% |
| Renal Failure |
2.9% |
| Tachycardia |
2.9% |
|
| Secondary |
| Chronic Lymphocytic Leukaemia |
29.6% |
| Drug Use For Unknown Indication |
9.8% |
| Product Used For Unknown Indication |
7.8% |
| B-cell Lymphoma |
7.3% |
| Acute Lymphocytic Leukaemia |
5.8% |
| Non-hodgkin's Lymphoma |
4.7% |
| Prophylaxis Against Graft Versus Host Disease |
4.6% |
| Prophylaxis |
4.0% |
| Stem Cell Transplant |
3.2% |
| Bone Marrow Conditioning Regimen |
3.0% |
| Mantle Cell Lymphoma |
2.9% |
| Acute Myeloid Leukaemia |
2.6% |
| Chromosome Analysis Abnormal |
2.6% |
| Premedication |
2.5% |
| T-cell Lymphoma |
2.1% |
| Lymphoma |
1.7% |
| Precursor T-lymphoblastic Lymphoma/leukaemia |
1.6% |
| Hodgkin's Disease |
1.4% |
| Breast Cancer |
1.4% |
| Lung Neoplasm Malignant |
1.4% |
|
| Myelodysplastic Syndrome |
11.1% |
| Infection |
10.0% |
| Thrombocytopenia |
9.0% |
| Febrile Neutropenia |
7.9% |
| Pyrexia |
5.6% |
| Progressive Multifocal Leukoencephalopathy |
5.5% |
| Vomiting |
5.3% |
| Death |
5.2% |
| Sepsis |
5.2% |
| Hepatitis B |
4.1% |
| Cytomegalovirus Infection |
3.5% |
| Neutropenia |
3.3% |
| Pancytopenia |
3.3% |
| Septic Shock |
3.2% |
| Infusion Related Reaction |
3.0% |
| Neutropenic Sepsis |
3.0% |
| Pneumonia |
3.0% |
| Tumour Flare |
2.9% |
| White Blood Cell Count Decreased |
2.9% |
| Respiratory Failure |
2.7% |
|
| Concomitant |
| Prophylaxis Against Graft Versus Host Disease |
15.8% |
| Drug Use For Unknown Indication |
11.4% |
| Stem Cell Transplant |
11.2% |
| Product Used For Unknown Indication |
10.1% |
| Bone Marrow Conditioning Regimen |
7.7% |
| Chronic Lymphocytic Leukaemia |
7.3% |
| Prophylaxis |
6.4% |
| Cord Blood Transplant Therapy |
6.0% |
| Premedication |
3.1% |
| B-cell Lymphoma |
2.8% |
| Acute Myeloid Leukaemia |
2.8% |
| Lymphoma |
2.7% |
| Non-hodgkin's Lymphoma |
2.3% |
| Graft Versus Host Disease |
2.2% |
| Antifungal Prophylaxis |
1.8% |
| Chemotherapy |
1.5% |
| Surgical Preconditioning |
1.5% |
| Bone Marrow Transplant |
1.4% |
| Infection Prophylaxis |
1.0% |
| Antiviral Prophylaxis |
0.9% |
|
| Drug Ineffective |
17.8% |
| Progressive Multifocal Leukoencephalopathy |
7.7% |
| Pyrexia |
7.7% |
| Graft Versus Host Disease |
6.2% |
| Thrombocytopenia |
5.6% |
| Sepsis |
5.3% |
| Transplant Rejection |
5.3% |
| Death |
4.7% |
| Infection |
3.8% |
| Vomiting |
3.8% |
| Weight Decreased |
3.8% |
| Thrombotic Microangiopathy |
3.6% |
| White Blood Cell Count Decreased |
3.6% |
| Neutropenia |
3.3% |
| Septic Shock |
3.3% |
| Acute Graft Versus Host Disease |
3.0% |
| Cytomegalovirus Infection |
3.0% |
| Syncope |
3.0% |
| Venoocclusive Disease |
3.0% |
| Aplasia Pure Red Cell |
2.7% |
|
| Interacting |
| Bone Marrow Conditioning Regimen |
34.7% |
| Prophylaxis Against Graft Versus Host Disease |
16.7% |
| Chronic Lymphocytic Leukaemia |
15.3% |
| Pyrexia |
9.7% |
| Prophylaxis |
6.9% |
| Product Used For Unknown Indication |
5.6% |
| Drug Use For Unknown Indication |
4.2% |
| Non-hodgkin's Lymphoma |
4.2% |
| Dyslipidaemia |
1.4% |
| Gout |
1.4% |
|
| Hepatitis Fulminant |
27.3% |
| Mucosal Inflammation |
27.3% |
| Lung Infection |
9.1% |
| Neurotoxicity |
9.1% |
| Pseudomonas Infection |
9.1% |
| Toxicity To Various Agents |
9.1% |
| Tumour Lysis Syndrome |
9.1% |
|
